MorphoSys AG has agreed to pay $13 million for rights to an anti-CD19 monoclonal antibody that is scheduled to start a Phase 1 study in cancer patients in the US shortly. It is the company’s first in-licensing deal for a clinical compound. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
